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Abstract
Background. The clinical course of primary hyperoxal-
uria (PH) is greatly variable and diagnosis is often
delayed. Little is known about the overall occurrence
and current prognosis.
Methods. We evaluated all known patients with PH
residing and observed in Switzerland during the last
15 years with the help of a survey among Swiss
nephrologists.
Results. Of the 25 patients observed between 7/79 and
6/94 in Switzerland, 18 were alive in 1994—14 on
conservative therapy and four on renal replacement
therapy (RRT). Twenty-two patients had PH type 1;
the exact type was not determined in three. The estim-
ated prevalence of PH (type 1) is 2 per million popula-
tion; the minimal incidence is 1 per 100000 live births.
Diagnosis was delayed by 8 years (median) except
in infants. Five patients were pyridoxine sensitive.
According to life table analysis, 20% of patients were
in end-stage renal failure (ESRF) and 10% had died
by the age of 15 years, and 50% were in ESRF and
20% dead at 25 years. Prognosis has improved: Five
of 13 patients died during the first half of the observa-
tion period as opposed to two of 20 in the second part.
Conclusions. Overall prognosis appears better than
hitherto believed considering the large clinical spectrum
of PH. Greater awareness of PH is needed to improve
further long-term prognosis.
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about its occurrence. While reviewing all known
patients with PH observed during the last 15 years in
Switzerland, we noticed a trend towards more frequent,
albeit still considerably delayed, diagnosis of PH and
a milder course. PH may be less rare than anticipated
and prognosis may be better than hitherto believed.
Subjects and methods
Paediatric and adult nephrologists were contacted about all
patients with PH residing in Switzerland and treated between
7/79 and 6/94. The total population in Switzerland in 1994
was 7.038 million and the number of children born during
these 15 years (1978-1993) was 1.172 million. Diagnosis of
PH was based on repeatedly elevated oxalate excretion
(normal <0.5mmol/24h per 1.73 m2), reduced activity of
alanine: glyoxylate aminotransferase (AGT) or generalized
oxalosis in ESRF after exclusion of secondary hyperoxaluria.
Urinary glycolate was measured in 21 patients [3]. The
actuarial curves for patient and (native) kidney survival were
calculated according to life table methods (Kaplan-Meier).
Renal death as the end-point was defined as the age ESRF
occurred, i.e. start of dialysis or death from uraemia.
Results
Twenty-five patients with PH were observed during
the last 15 years; 16 were males (Figure 1). PH was
diagnosed in seven patients during the first half of the
Introduction
Primary hyperoxaluria (PH), particularly its most
common form, type 1, is characterized by increased
production of oxalic acid, resulting in recurrent uroli-
thiasis and nephrocalcinosis which often progresses
to end-stage renal failure (ESRF) and generalized
oxalosis [1,2]. The clinical spectrum of PH is very
large and patients are seen at all ages. Little is known
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Fig. 1. Year of diagnosis and subsequent clinical course.
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Table 1. Age (years) at first clinical symptoms/signs and at diagnosis of PH
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Age group (n) A 7* B 12* C 6
Age at first symptoms/signs (median)
(range)
Age at diagnosis (median)
(range)
0.3
(0.1-0.5)
0.6
(0.1-2.7)
4.3
(2-13)
12
(2.5-38)
24
(15-37)
34.5
(21-62)
* Less one patient without symptoms detected by family screening.
observation period and in 12 during the second part;
in six, diagnosis was known before 1979. Twenty-two
patients were classified as type 1 of PH, based on
elevated urinary glycolate excretion (19 patients) or
diminished hepatic AGT activity (3 patients). The
exact type of PH in the remaining three patients could
not be established. No case of PH type 2 was dia-
gnosed. As of June 1994, 18 patients were alive; of
these, 14 (all with type 1) did not require renal replace-
ment therapy (RRT), suggesting a prevalence of 2 per
million population. Renal function was normal or
slightly impaired (serum creatinine <100umol/l) in
11 of these 14 patients, moderately decreased (serum
creatinine < 150 umol/1) in two and severely impaired
in one (serum creatinine 200 umol/1). Diagnosis of PH
(type 1) was made 12 times in children born during
the study period. The calculated (minimal) incidence
is 1 in 98 000 live births.
According to the age at first clinical symptoms,
patients were assigned to three age groups: A <2
years, B 2-14 years, and C >14 years. Except for
patients in group A who frequently had a severe course,
diagnosis was usually considerably delayed, being
made almost 8 years (median) after the first clinical
manifestations in group B, and even after 10.5 years
in C (Table 1, Figure 2). Recurrent urolithiasis was
the leading symptom in 83% of patients in groups B
and C in contrast to failure to thrive or anaemia due
to renal failure in infants.
The symptoms or signs that ultimately led to dia-
gnosis of PH were nephrocalcinosis (7), ESRF (6) and
urolithiasis (5). Six of the seven remaining patients
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Fig. 2. Age at first clinical manifestation and clinical course. Time
of diagnosis is indicated by vertical bar.
with no obvious symptoms were diagnosed by family
screening and one was detected by abdominal ultra-
sonography performed for other reasons. Fourteen
patients had both urolithiasis and nephrocalcinosis,
five had stones but no detectable nephrocalcinosis, and
another five had isolated nephrocalcinosis. Only one
patient, detected by family screening, had normal renal
echography.
Altogether there were 15 familial cases belonging to
eight families. Seven families had two affected siblings
(in 2 instances, only 1 member is included in the study
because of death of the sibling before 1979 and resid-
ency outside Switzerland respectively). One further
family shows apparent autosomal inheritance involving
son, mother, and maternal uncle; whereas both adult
patients had a concordant clinical course (group C),
the son presented with infantile oxalosis (A) [4]. PH
is concordant in five of the other seven families
(3 x B/B and 2 x C/C) and discordant in one (B/C).
Classification is arbitrary in one family because the
8-year-old sister of a patient with infantile oxalosis
(A) never had clinical symptoms despite nephrocal-
cinosis detected shortly after birth. The vast majority
of patients (20) were of Swiss origin; four (3 families)
came from former Yugoslavia and one from Italy.
There was no proven consanguinity.
Five patients were pyridoxine sensitive. Three have
been reported previously [4,5]; the other two had
reduction of oxalate excretion by nearly one-half. The
actuarial survival curves for kidneys and patients run
parallel with most losses occurring after the age of 20
years (Figure 3). By the age of 15 years 20% of the
patients were in ESRF and 10% had died. By the age
of 25 years, half of the patients were in ESRF and
20% were dead. Almost identical data were obtained
in the subgroup of 22 patients with documented PH
type 1. Of seven patients undergoing isolated kidney
transplantation, only one is alive. Two further patients
underwent combined liver/kidney transplantation and
are alive. General outlook has considerably changed:
Whereas five of 13 patients diagnosed before 1986 were
dead by then, only two of 20 patients died since 1987.
Discussion
The aim of this study was to record all patients with
PH seen during 1.5 decades in one country, so as to
eliminate bias by selection. Urologists were not con-
tacted, since paediatric stone patients in Switzerland
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Actuarial Survival in 25 Patients with PH
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Fig. 3. Actuarial survival in 25 patients with PH. End-points are age at renal death and age at death of the patient.
are seen by paediatric nephrologists and adult patients
with a metabolic stone disease are referred to nephrolo-
gists. However, it is likely that not all patients with
PH were detected. Indeed, diagnosis of PH was estab-
lished thanks to family screening—and not on clinical
grounds—in almost one-quarter of all patients, who
otherwise would have been missed. The estimated
prevalence rate (2 per million for type 1) therefore is
a minimum figure. The same applies to the estimated
incidence (calculated per live births) since there is little
doubt that diagnosis of PH has not yet been made
in every patient born during the study period.
Comparatively more patients were diagnosed in the
last few years, possibly thanks to greater awareness
of PH.
Published data concerning the prevalence of PH are
scarce. In a recent survey in France (1988-1992), a
prevalence rate of 1.04 per million was calculated for
PH type 1 [6]. The Swiss figure is almost twice as
high. Only 17 patients were observed in Scandinavia
during 10 years (1967-1976); 10 were alive at the end
of that period [7].
The very large clinical spectrum of PH (primarily
type 1) has again been demonstrated and may be one
reason why diagnosis was so often delayed. Indeed, six
patients were already in ESRF when PH was dia-
gnosed. The clinical heterogeneity is not sufficiently
explained by remaining activity of the peroxisomal
enzyme AGT or by mitochondrial mistargeting; other
factors (e.g. episodes of dehydration) are important as
well [ 1 ]. Initial symptoms may be very vague (e.g. inter-
mittent abdominal pain), and a high level of suspicion
is needed.
Much progress has been made unravelling the
molecular basis of PH type 1 [1], but clinical assess-
ment still runs far behind. Normal urinary oxalate/
creatinine ratios for different age groups are available
for screening purposes [3,8].
The prognosis of PH has to be reassessed in the
light of this study. Whereas 50% of children were
reported to reach ESRF before age 15 [2], this was
the case in only 20% of our patients according to life
table analysis. However, the actuarial data must be
interpreted with caution because of the low number of
older patients. It is likely that previous studies (see
[2]) were biased towards patients with serious and
early clinical manifestation. Furthermore the general
outlook seems to have improved, thanks to greater
awareness of PH, leading to earlier diagnosis and
intervention. Renal failure may thus be prevented or
delayed [5,9,10], at least as long as renal function is
not seriously compromised. Such conservative meas-
ures are far more economical and simpler than com-
bined liver-kidney transplantation, at present the best
form of renal replacement therapy in PH type 1 [11].
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